Paris, Apr 12 (EFE).- French pharmaceutical giant Sanofi announced Monday that it will invest €400 million ($475.3 million) over five years into a new vaccine production facility in Singapore.
“The new site will provide Sanofi with the ability to produce innovative vaccines on a massive scale for Asia, and quickly respond to future pandemic risks,” the company said in a statement.
Construction of the factory is set to begin in the third quarter of this year and be fully operational in the first quarter of 2026, when it’s set to start “pushing the boundaries of operations through cutting edge manufacturing and digital technologies.”
The complex, built in partnership with the Singapore Economic Development Board, will use state-of-the-art manufacturing technologies and is expected to create up to 200 local jobs.
“By investing in a new production site in Singapore, Sanofi is aiming to strengthen production capacity to meet ever-growing global demands on vaccines, and answer more rapidly to future pandemics,” said Thomas Triomphe, executive vice president and global head of Sanofi Pasteur, in the statement.
It will be designed around a central unit housing several fully digitalized modules that allow production of three to four vaccines simultaneously, contrasting with current sites that only allow one.
The site is expected to be carbon-neutral, and to reduce consumption of resources and production of waste.
Sanofi says the Singapore site will complement the company’s existing manufacturing capacities in Europe and North America. EFE